BB&T Investment Services Inc. Acquires Shares of 1,051 Regeneron Pharmaceuticals, Inc. (REGN)

BB&T Investment Services Inc. acquired a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund acquired 1,051 shares of the biopharmaceutical company’s stock, valued at approximately $503,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Fieldpoint Private Securities LLC bought a new stake in shares of Regeneron Pharmaceuticals in the second quarter worth $130,000. Sterling Investment Advisors Ltd. lifted its position in Regeneron Pharmaceuticals by 11.2% during the second quarter. Sterling Investment Advisors Ltd. now owns 278 shares of the biopharmaceutical company’s stock valued at $137,000 after purchasing an additional 28 shares in the last quarter. FNY Managed Accounts LLC purchased a new position in Regeneron Pharmaceuticals during the first quarter valued at $140,000. FNY Partners Fund LP lifted its position in Regeneron Pharmaceuticals by 200.0% during the second quarter. FNY Partners Fund LP now owns 300 shares of the biopharmaceutical company’s stock valued at $147,000 after purchasing an additional 200 shares in the last quarter. Finally, Alpha Windward LLC lifted its position in Regeneron Pharmaceuticals by 0.3% during the second quarter. Alpha Windward LLC now owns 384 shares of the biopharmaceutical company’s stock valued at $189,000 after purchasing an additional 1 shares in the last quarter. 67.41% of the stock is owned by institutional investors.

In related news, SVP Robert E. Landry sold 526 shares of the firm’s stock in a transaction dated Tuesday, August 8th. The shares were sold at an average price of $472.19, for a total value of $248,371.94. Following the transaction, the senior vice president now directly owns 9,099 shares of the company’s stock, valued at approximately $4,296,456.81. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, SVP Robert E. Landry sold 468 shares of the firm’s stock in a transaction dated Wednesday, August 23rd. The shares were sold at an average price of $476.45, for a total transaction of $222,978.60. Following the completion of the transaction, the senior vice president now directly owns 9,099 shares in the company, valued at $4,335,218.55. The disclosure for this sale can be found here. Insiders sold a total of 89,468 shares of company stock worth $42,312,448 over the last ninety days. 10.80% of the stock is currently owned by corporate insiders.

This article was originally published by and is the sole property of Zolmax. If you happen to be reading this article on another website, it was stolen and illegally republished in violation of U.S. and International copyright law. The original version of this story can be read at https://zolmax.com/investing/bbt-investment-services-inc-acquires-shares-of-1051-regeneron-pharmaceuticals-inc-regn/1707394.html

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) traded down 0.6228% during midday trading on Thursday, hitting $450.1487. The company had a trading volume of 234,571 shares. The company has a 50 day moving average price of $459.39 and a 200 day moving average price of $454.48. Regeneron Pharmaceuticals, Inc. has a 1-year low of $325.35 and a 1-year high of $543.55. The firm has a market capitalization of $47.73 billion, a P/E ratio of 45.1594 and a beta of 1.62.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported $4.17 earnings per share for the quarter, beating the Zacks’ consensus estimate of $2.67 by $1.50. The firm had revenue of $1.47 billion for the quarter, compared to analyst estimates of $1.36 billion. Regeneron Pharmaceuticals had a net margin of 22.05% and a return on equity of 25.58%. Regeneron Pharmaceuticals’s quarterly revenue was up 21.2% compared to the same quarter last year. During the same period last year, the company posted $2.82 EPS. Equities research analysts forecast that Regeneron Pharmaceuticals, Inc. will post $14.92 earnings per share for the current fiscal year.

Several equities analysts recently weighed in on the company. Zacks Investment Research downgraded Regeneron Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday. Morgan Stanley reiterated an “equal weight” rating and set a $490.00 target price (up from $450.00) on shares of Regeneron Pharmaceuticals in a research report on Friday, October 6th. Jefferies Group LLC reiterated a “hold” rating and set a $500.00 target price (up from $471.00) on shares of Regeneron Pharmaceuticals in a research report on Friday, October 6th. SunTrust Banks, Inc. reiterated a “hold” rating and set a $435.00 target price on shares of Regeneron Pharmaceuticals in a research report on Monday, October 2nd. Finally, Piper Jaffray Companies reiterated an “overweight” rating and set a $540.00 target price on shares of Regeneron Pharmaceuticals in a research report on Friday, September 29th. Three equities research analysts have rated the stock with a sell rating, fourteen have issued a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $489.92.

COPYRIGHT VIOLATION NOTICE: “BB&T Investment Services Inc. Acquires Shares of 1,051 Regeneron Pharmaceuticals, Inc. (REGN)” was reported by Zolmax and is owned by of Zolmax. If you are viewing this piece of content on another publication, it was stolen and republished in violation of international trademark & copyright legislation. The legal version of this piece of content can be read at https://zolmax.com/investing/bbt-investment-services-inc-acquires-shares-of-1051-regeneron-pharmaceuticals-inc-regn/1707394.html.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Bco Com Portugues  Given Consensus Rating of “Sell” by Analysts
Bco Com Portugues Given Consensus Rating of “Sell” by Analysts
GSA Capital Partners LLP Invests $258,000 in Aerie Pharmaceuticals, Inc.  Stock
GSA Capital Partners LLP Invests $258,000 in Aerie Pharmaceuticals, Inc. Stock
Crestwood Equity Partners LP  Shares Sold by GSA Capital Partners LLP
Crestwood Equity Partners LP Shares Sold by GSA Capital Partners LLP
GSA Capital Partners LLP Invests $270,000 in Sabra Healthcare REIT, Inc.  Stock
GSA Capital Partners LLP Invests $270,000 in Sabra Healthcare REIT, Inc. Stock
Citigroup Inc. Buys 897 Shares of WisdomTree Internationl Dvdnd Ex Fncl Fd
Citigroup Inc. Buys 897 Shares of WisdomTree Internationl Dvdnd Ex Fncl Fd
First Bancorp  Shares Sold by GSA Capital Partners LLP
First Bancorp Shares Sold by GSA Capital Partners LLP


Leave a Reply

 
© 2006-2017 Zolmax.